CPDR Integrated Biomedical Informatics Platform
Developing Effective Prevention, Diagnostic and Treatment Strategies
The infrastructure of Integrated Biomedical Informatics Platform (IBIP) has been established with business requirement analysis, platform blueprint, implementation strategies, and organization-wide policies, standards on information management and information system development. Program-specific resource informatics systems are also constructed via setting up sophisticated and robust information systems and tools in each research program to streamline the in-house information management by its own requirements. The construction of those systems follows policies, standards and SOPs regulated by the platform. They can be deployed onto IBIP, which:
- Enable the programmable connection between resource informatics systems and the platform as a network to facilitate data communication, and to implement interoperability
- Facilitate dynamic and seamless interdisciplinary data integration and annotation via dynamic data binding
- Provide systematic solution to data quality monitoring and control, data query, data sharing, distribution and version control.
- Provide comprehensive strategies and solution to information security, human privacy protection and regulatory compliance on data collection, integration, analysis and management
- Establish policies, standards, and SOPs on organization level and research program level for operation within information system, data management, and information sharing in collaboration
- Provide professional administration on information system and databases
Patient's privacy protection and data security are two most critical and most challenging factors regarding the research data management. Within IBIP, multiple strategies are applied to ensure the privacy protection and data security.
Privacy protection is ensured by processes of automated data de-identification and centralized patient identification. De-identification enforces the filtering and localized storage of demographic information collected by data management systems. Centralized patient identification will make sure patients consenting to the program are uniquely assigned a random selected identification number, which will serve as the primary patient identification in centralized, de-identified research data pool, and the only linkage between local demographic databases and central research databases.
September 29, 2014
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).
Read Full Article.
Read Publication - European Urology
February 2015 Guest Speaker
Colonel Robert C. Dean, MD
Director of Andrology, WRNMMC
Presentation: "SEXUAL HEALTH AND PROSTATE CANCER"
Date: 5 February 2015
Time: 7-8:30 PM
Location: WRNMMC, America Building, 2nd floor, Room 2525
Contact: COL (ret) Jane Hudak for more information at 301-319-2918 or
(The presentation also may be viewed via video teleconference at the Fort Belvoir Community Hospital. Go to the Oaks Pavilion, 1st floor, Room 332, to participate.)